Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Zacks.com on MSN2d
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...
FiercePharma18h
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...
FierceBiotech3d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...
BioSpace3d
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...
FierceBiotech11d
Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data
Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. | Merck & ...
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...
Reuters4d
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...